Page 50 - CPG endometrial cancer
P. 50
รศ.พญ.อาบอรณุ เลิศขจรสขุ
and a BRCA1/ 2 mutation ( SOLO2/ ENGOT-
Ov21): a double blind, randomised, placebo-
controlled, phase3 trial. Lancet Oncol
2017:18:1274-84.
16. Poveda A, Floquet A, Lederman J, Asher
R, Penson R, Oza A, et al. Final overall
survival results from SOLO2/ ENGOT- ov21: a
phase III trial assessing maintenance olaparib
in patients with platinum- sensitive relapsed
ovarian cancer and a BRCA mutation. Presented
at the American Society of Clinical Oncology
Annual Meeting 2020.
41
